Information Provided By:
Fly News Breaks for January 7, 2020
Jan 7, 2020 | 08:17 EDT
Baird analyst Madhu Kumar raised his price target on Apellis to $70 from $45 following the release of its top-line Phase 3 PEGASUS data that validated their conviction for its lead asset APL-2 for paroxysmal nocturnal hemoglobinuria (PNH). The analyst believes the positive results support his bullishness to improve PNH treatment particularly in terms of extravascular hemolysis (EMH) driven anemia. Kumar reiterated his Outperform rating and Fresh Pick designation on Apellis shares.
News For APLS From the Last 2 Days
There are no results for your query APLS